礼来
LLY1071.390USD
-5.090-0.47%
收盘 12/23, 16:00（美东）报价延迟15分钟
1.01T总市值
52.28市盈率 TTM
关于 礼来 公司
礼来公司是全球知名的创新药物巨头，专注于在人用医药领域的研发、制造与销售。其糖尿病、肥胖及心脏代谢线代表药品含 Basaglar、Humalog、Mounjaro、Trulicity 与 Zepbound（体重管理）；肿瘤产品涵盖 Alimta、Retevmo、Tyvyt、Verzenio；免疫学阵容包含 Ebglyss、Olumiant、Omvoh、Taltz；神经科学线提供 Cymbalta、Emgality；其他重点品牌及疗法尚有 Cialis、Forteo。公司透过 POINT Biopharma 深耕放射性药物研发，并开发 α4β7 抑制剂 MORF-057 治疗 IBD，同时投资 AI 药物设计与数字临床平台以加速候选药上市。
礼来简介
公司代码LLY
公司名称Eli Lilly and Co
上市日期Jul 09, 1970
CEORicks (David A)
员工数量47000
证券类型Ordinary Share
年结日Jul 09
公司地址Lilly Corporate Ctr
城市INDIANAPOLIS
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编46285
电话13172762000
网址https://www.lilly.com/
公司代码LLY
上市日期Jul 09, 1970
CEORicks (David A)
礼来公司高管
名称
名称/职务
职务
持股
持股变动
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.57K
+0.30%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.37K
+0.93%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
19.72K
+77.63%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
14.69K
+5.12%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
9.84K
+15.72%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.57K
+0.30%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Diabetes-Mounjaro
5.20B
33.42%
Diabetes-Zepbound
3.38B
21.73%
Oncology-Verzenio
1.49B
9.57%
Diabetes-Trulicity
1.09B
7.02%
Diabetes-Other Diabetes
980.40M
6.30%
其他
3.42B
21.95%
地区USD
名称
营收
占比
U.S.
10.81B
69.51%
Europe
2.57B
16.55%
Other foreign countries
1.18B
7.60%
Japan
521.00M
3.35%
China
465.90M
2.99%
业务
地区
业务USD
名称
营收
占比
Diabetes-Mounjaro
5.20B
33.42%
Diabetes-Zepbound
3.38B
21.73%
Oncology-Verzenio
1.49B
9.57%
Diabetes-Trulicity
1.09B
7.02%
Diabetes-Other Diabetes
980.40M
6.30%
其他
3.42B
21.95%
股东统计
更新时间: 11月12日 周三
更新时间: 11月12日 周三
持股股东
股东类型
持股股东
持股股东
占比
Lilly Endowment, Inc.
9.75%
The Vanguard Group, Inc.
8.52%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
其他
68.21%
持股股东
持股股东
占比
Lilly Endowment, Inc.
9.75%
The Vanguard Group, Inc.
8.52%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
其他
68.21%
股东类型
持股股东
占比
Investment Advisor
45.37%
Investment Advisor/Hedge Fund
18.69%
Foundation
9.75%
Research Firm
2.04%
Pension Fund
1.89%
Bank and Trust
1.84%
Insurance Company
1.48%
Sovereign Wealth Fund
1.29%
Hedge Fund
0.74%
其他
16.91%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
5762
789.85M
83.53%
-6.48M
2025Q2
5717
798.76M
84.28%
+2.87M
2025Q1
5710
800.38M
84.44%
+5.04M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
2023Q2
4197
799.48M
84.22%
-4.32M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Lilly Endowment, Inc.
95.49M
10.09%
-243.99K
-0.25%
Sep 30, 2025
The Vanguard Group, Inc.
80.05M
8.46%
+1.17M
+1.49%
Jun 30, 2025
PNC Investments LLC
51.08M
5.4%
-9.49K
-0.02%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
41.30M
4.36%
-168.44K
-0.41%
Jun 30, 2025
State Street Investment Management (US)
34.51M
3.65%
+69.02K
+0.20%
Jun 30, 2025
Capital Research Global Investors
20.76M
2.19%
+5.01M
+31.81%
Jun 30, 2025
Fidelity Management & Research Company LLC
24.36M
2.57%
-2.82M
-10.39%
Jun 30, 2025
Geode Capital Management, L.L.C.
18.13M
1.92%
-397.62K
-2.15%
Jun 30, 2025
Capital World Investors
17.63M
1.86%
-748.08K
-4.07%
Jun 30, 2025
Wellington Management Company, LLP
13.99M
1.48%
+1.28M
+10.09%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
VanEck Pharmaceutical ETF
47.56%
iShares U.S. Pharmaceuticals ETF
25.23%
Harbor Health Care ETF
18.24%
Roundhill GLP-1 & Weight Loss ETF
16.7%
Health Care Select Sector SPDR Fund
14.06%
Proshares Ultra Health Care
13.57%
iShares U.S. Healthcare ETF
13.54%
Amplify Weight Loss Drug & Treatment ETF
11.93%
Fidelity MSCI Health Care Index ETF
11.73%
Goldman Sachs Future Health Care Equity ETF
10.84%
查看更多
VanEck Pharmaceutical ETF
占比47.56%
iShares U.S. Pharmaceuticals ETF
占比25.23%
Harbor Health Care ETF
占比18.24%
Roundhill GLP-1 & Weight Loss ETF
占比16.7%
Health Care Select Sector SPDR Fund
占比14.06%
Proshares Ultra Health Care
占比13.57%
iShares U.S. Healthcare ETF
占比13.54%
Amplify Weight Loss Drug & Treatment ETF
占比11.93%
Fidelity MSCI Health Care Index ETF
占比11.73%
Goldman Sachs Future Health Care Equity ETF
占比10.84%
分红派息
近5年累计派现
18.06B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Oct 27, 2025
LLY.NB Final Cash Dividend of gross USD 1.5 paid on Dec 10, 2025 going ex on Nov 14, 2025
Nov 14, 2025
Dec 10, 2025
Nov 14, 2025
Jun 23, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Sep 10, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 10, 2025
Aug 15, 2025
May 05, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Jun 10, 2025 going ex on May 16, 2025
May 16, 2025
Jun 10, 2025
May 16, 2025
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
Jun 26, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023
Aug 15, 2023
Sep 08, 2023
Aug 14, 2023
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
礼来的前五大股东是谁？
礼来 的前五大股东如下：
Lilly Endowment, Inc.持有股份：95.49M，占总股份比例：10.09%。
The Vanguard Group, Inc.持有股份：80.05M，占总股份比例：8.46%。
PNC Investments LLC持有股份：51.08M，占总股份比例：5.40%。
BlackRock Institutional Trust Company, N.A.持有股份：41.30M，占总股份比例：4.36%。
State Street Investment Management (US)持有股份：34.51M，占总股份比例：3.65%。
Lilly Endowment, Inc.持有股份：95.49M，占总股份比例：10.09%。
The Vanguard Group, Inc.持有股份：80.05M，占总股份比例：8.46%。
PNC Investments LLC持有股份：51.08M，占总股份比例：5.40%。
BlackRock Institutional Trust Company, N.A.持有股份：41.30M，占总股份比例：4.36%。
State Street Investment Management (US)持有股份：34.51M，占总股份比例：3.65%。
礼来的前三大股东类型是什么？
礼来 的前三大股东类型分别是：
Lilly Endowment, Inc.
The Vanguard Group, Inc.
PNC Investments LLC
Lilly Endowment, Inc.
The Vanguard Group, Inc.
PNC Investments LLC
有多少机构持有礼来(LLY)的股份？
截至2025Q3，共有5762家机构持有礼来的股份，合计持有的股份价值约为789.85M，占公司总股份的83.53%。与2025Q2相比，机构持股有所增加，增幅为-0.75%。
哪个业务部门对礼来的收入贡献最大？
在FY2025Q2，Diabetes-Mounjaro业务部门对礼来的收入贡献最大，创收5.20B，占总收入的33.42%。
